S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
The single greatest medical breakthrough of all time? (Ad)
Can Investors Win the Race with Dividend Achiever Nike?
CarMax Slides On Earnings Disappointment, Time To Celebrate?
66,000% upside on tiny biotech? (Ad)
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The World's First "$20 Trillion Drug (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
The single greatest medical breakthrough of all time? (Ad)
Can Investors Win the Race with Dividend Achiever Nike?
CarMax Slides On Earnings Disappointment, Time To Celebrate?
66,000% upside on tiny biotech? (Ad)
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The World's First "$20 Trillion Drug (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
The single greatest medical breakthrough of all time? (Ad)
Can Investors Win the Race with Dividend Achiever Nike?
CarMax Slides On Earnings Disappointment, Time To Celebrate?
66,000% upside on tiny biotech? (Ad)
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The World's First "$20 Trillion Drug (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
The Next Stage Of Google’s Rally Just Started
The single greatest medical breakthrough of all time? (Ad)
Can Investors Win the Race with Dividend Achiever Nike?
CarMax Slides On Earnings Disappointment, Time To Celebrate?
66,000% upside on tiny biotech? (Ad)
Costco Isn't Facing Devastating Surges in Theft Like Target and Walmart — and the Reason Is Very Simple
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The World's First "$20 Trillion Drug (Ad)
4 Proven Strategies to Help You Find Success in Executive Leadership
'Control, Surveillance and Manipulation': How TikTok's Office Surveillance Could Backfire and Cost The Company Billions
NASDAQ:CCCC

C4 Therapeutics (CCCC) Stock Forecast, Price & News

$1.86
+0.02 (+1.09%)
(As of 09/29/2023 ET)
Compare
Today's Range
$1.85
$1.97
50-Day Range
$1.81
$3.89
52-Week Range
$1.72
$10.42
Volume
270,963 shs
Average Volume
501,445 shs
Market Capitalization
$91.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.13

C4 Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
444.4% Upside
$10.13 Price Target
Short Interest
Bearish
5.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of C4 Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.69) to ($2.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

798th out of 972 stocks

Biological Products, Except Diagnostic Industry

130th out of 159 stocks


CCCC stock logo

About C4 Therapeutics (NASDAQ:CCCC) Stock

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

CCCC Price History

CCCC Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
12 Best High Risk Penny Stocks to Buy Now
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
C4 Therapeutics Appoints Leonard Reyno As CMO
The Latest Analyst Ratings for C4 Therapeutics
See More Headlines
Receive CCCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CCCC Company Calendar

Last Earnings
8/08/2023
Today
9/30/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CCCC
Fax
N/A
Employees
146
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.13
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+444.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
7 Analysts

Profitability

Net Income
$-128,180,000.00
Net Margins
-872.34%
Pretax Margin
-872.34%

Debt

Sales & Book Value

Annual Sales
$31.10 million
Book Value
$5.91 per share

Miscellaneous

Free Float
45,270,000
Market Cap
$91.49 million
Optionable
Not Optionable
Beta
2.07
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Andrew J. Hirsch M.B.A. (Age 52)
    CEO, Pres & Director
    Comp: $971k
  • Dr. Kenneth C. Anderson M.D. (Age 72)
    Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board
    Comp: $39.03k
  • Dr. Stewart FisherDr. Stewart Fisher (Age 56)
    Chief Scientific Officer
    Comp: $657.34k
  • Mr. Scott N. Boyle M.B.A. (Age 45)
    Ph.D., Chief Bus. Officer
    Comp: $672.78k
  • Dr. Nathanael S. Gray Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Ms. Lauren A. White M.B.A. (Age 44)
    CFO & Treasurer
  • Ms. Kendra Adams
    Sr. VP of Communications & Investor Relations
  • Ms. Jolie M. Siegel J.D. (Age 46)
    Chief Legal Officer & Corp. Sec.
  • Ms. Kelly A. Schick (Age 43)
    Chief People Officer
  • Dr. Isabel Chiu Ph.D.
    Sr. VP of Strategic Alliances & Bus. Devel.













CCCC Stock - Frequently Asked Questions

Should I buy or sell C4 Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CCCC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CCCC, but not buy additional shares or sell existing shares.
View CCCC analyst ratings
or view top-rated stocks.

What is C4 Therapeutics' stock price forecast for 2023?

7 equities research analysts have issued 12 month target prices for C4 Therapeutics' stock. Their CCCC share price forecasts range from $5.00 to $20.00. On average, they expect the company's stock price to reach $10.13 in the next year. This suggests a possible upside of 444.4% from the stock's current price.
View analysts price targets for CCCC
or view top-rated stocks among Wall Street analysts.

How have CCCC shares performed in 2023?

C4 Therapeutics' stock was trading at $5.90 at the beginning of 2023. Since then, CCCC stock has decreased by 68.5% and is now trading at $1.86.
View the best growth stocks for 2023 here
.

Are investors shorting C4 Therapeutics?

C4 Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 2,380,000 shares, an increase of 14.4% from the August 31st total of 2,080,000 shares. Based on an average daily trading volume, of 990,300 shares, the days-to-cover ratio is currently 2.4 days. Approximately 5.9% of the shares of the stock are short sold.
View C4 Therapeutics' Short Interest
.

When is C4 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CCCC earnings forecast
.

How were C4 Therapeutics' earnings last quarter?

C4 Therapeutics, Inc. (NASDAQ:CCCC) issued its earnings results on Tuesday, August, 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.01. The company had revenue of $2.66 million for the quarter, compared to analyst estimates of $8.65 million. C4 Therapeutics had a negative net margin of 872.34% and a negative trailing twelve-month return on equity of 50.69%.

When did C4 Therapeutics IPO?

(CCCC) raised $150 million in an IPO on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

What is C4 Therapeutics' stock symbol?

C4 Therapeutics trades on the NASDAQ under the ticker symbol "CCCC."

How do I buy shares of C4 Therapeutics?

Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is C4 Therapeutics' stock price today?

One share of CCCC stock can currently be purchased for approximately $1.86.

How much money does C4 Therapeutics make?

C4 Therapeutics (NASDAQ:CCCC) has a market capitalization of $91.49 million and generates $31.10 million in revenue each year. The company earns $-128,180,000.00 in net income (profit) each year or ($2.85) on an earnings per share basis.

How many employees does C4 Therapeutics have?

The company employs 146 workers across the globe.

How can I contact C4 Therapeutics?

The official website for the company is www.c4therapeutics.com. The company can be reached via phone at 617-231-0700 or via email at jane.urheim@sternir.com.

This page (NASDAQ:CCCC) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -